Abstract
Inhibition of hepatic and intestinal CYP3A4 by mibefradil measured by the erythromycin breath test (EBT) and oral midazolam pharmacokinetics (PK)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have